Medical Care Technologies Inc. (OTCID:MDCE) Delivers Stronger Melanoma Scan Beta Readout on Expanded Human-Submitted Dataset

What happened

Medical Care Technologies said updated internal results for its Melanoma Scan Beta were posted on its website. On an expanded dataset of human-submitted images, 86% passed image-quality checks, 89% of usable images were placed on a body map, and 91% of paired images aligned for comparison over time.

Confirmed

Global impact / market context

The results describe technical steps needed for users to submit photos, locate skin areas, and compare them later. If those steps work reliably in broader use, they could support the product’s usefulness; weak performance could limit adoption and any related revenue, but the figures alone do not show commercial demand.

Analyst inference

These are internal evaluation measures, not reported sales, clinical outcomes, regulatory clearance, or evidence of profit. For investors, the readout offers an update on product development, while leaving unanswered whether the tool can be validated for real-world use and turned into a sustainable business.

Analyst inference

What to watch

1. Whether the company publishes further testing details, including how many images were assessed and whether results hold across different users and image conditions. Analyst inference
2. Whether the company reports plans for external validation or regulatory review; either could add evidence beyond this internal technical assessment, but no such plan is stated here. Analyst inference
3. Whether later disclosures show user uptake, revenue, or costs associated with developing and operating Melanoma Scan Beta; the article provides no commercial measures. Analyst inference

Evidence

• accessnewswire.com